NNC6019-0001 + Placebo (NNC6019-0001)

Phase 2Completed

2 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Conditions

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Trial Timeline

Aug 2, 2022 → May 13, 2025

NCT ID

NCT05442047

About NNC6019-0001 + Placebo (NNC6019-0001)

NNC6019-0001 + Placebo (NNC6019-0001) is a phase 2 stage product being developed by Novo Nordisk for Transthyretin Amyloid Cardiomyopathy (ATTR CM). The current trial status is completed. This product is registered under clinical trial identifier NCT05442047. Target conditions include Transthyretin Amyloid Cardiomyopathy (ATTR CM).

What happened to similar drugs?

3 of 19 similar drugs in Transthyretin Amyloid Cardiomyopathy (ATTR CM) were approved

Approved (3) Terminated (0) Active (16)

✅tafamidis megluminePfizerApproved

✅TafamidisPfizerApproved

✅AcoramidisBayerApproved

🔄Eplontersen + PlaceboAstraZenecaPhase 3

🔄EplontersenAstraZenecaPhase 3

🔄Eplontersen + PlaceboAstraZenecaPhase 3

🔄NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07207811	Phase 3	Recruiting	Oct 2, 2025	Jun 29, 2029	Transthyretin Amyloid Cardiomyopathy (ATTR CM)
NCT05442047	Phase 2	Completed	Aug 2, 2022	May 13, 2025	Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Competing Products

20 competing products in Transthyretin Amyloid Cardiomyopathy (ATTR CM)

See all competitors

Product	Company	Stage	Hype Score
Eplontersen Solution for Injection	AstraZeneca	Phase 1	29
Eplontersen + Placebo	AstraZeneca	Phase 3	44
Treatment of transthyretin (ATTR) amyloidosis in observational study setting	AstraZeneca	Pre-clinical	33
Eplontersen	AstraZeneca	Phase 3	47
Eplontersen + Placebo	AstraZeneca	Phase 3	44
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 3	47
NNC6019-0001	Novo Nordisk	Phase 2	39
Coramitug	Novo Nordisk	Phase 1	36
Tafamidis	Pfizer	Pre-clinical	26
Tafamidis	Pfizer	Pre-clinical	30
tafamidis meglumine	Pfizer	Approved	43
Fx-1006A	Pfizer	Phase 2	35
Tafamidis	Pfizer	Phase 3	40
Tafamidis 61 milligrams	Pfizer	Pre-clinical	26
Treatment for TTR amyloidosis + Treatment for TTR amyloidosis	Pfizer	Pre-clinical	26
Vyndaqel	Pfizer	Pre-clinical	26
tafamidis	Pfizer	Phase 3	40
Tafamidis	Pfizer	Approved	43
Tafamidis	Pfizer	Pre-clinical	26
Vyndamax (tafamidis 61mg)	Pfizer	Pre-clinical	30